Oruka Therapeutics is developing extended half-life monoclonal antibodies targeting IL-23p19 [ORKA-001] and IL-17A/F [ORKA-002] for autoimmune diseases. ORKA-001 aims for once-yearly dosing in ...
Hosted on MSN
Everlast Minerals Ltd Announces 2025 AGM Details
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Everlast Minerals Ltd ( (AU:EV8)) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback